CHIR-98014
Based on 10 publication(s) in Google Scholar
CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.
For research use only. We do not sell to patients.
- Purity: 98.44%
- CAS No.: 252935-94-7
- Formula: C20H17Cl2N9O2
- Molecular Weight:486.31
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) CHIR-98014
More- Cell Res. 2022 Jun;32(6):513-529. [Abstract]
- Cancer Res. 2019 Feb 1;79(3):534-545. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(23):e11606. [Abstract]
- Sci Adv. 2026 Mar 20;12(12):eadz5906. [Abstract]
- Food Chem Toxicol. 2025 Oct:204:115628. [Abstract]
- Hum Cell. 2024 Jul;37(4):1156-1169. [Abstract]
- SLAS Discov. 2024 Nov 5;29(8):100191. [Abstract]
- SSRN. 2025 Jul 25.
- bioRxiv. 2024 September 07.
- SSRN. 2023 Jun 20.
Biological Activity
|
GSK-3β 0.58 nM (IC50) |
GSK-3α 0.65 nM (IC50) |
cdc2 3700 nM (IC50) |
CHIR 98014 inhibits human GSK-3β with Ki value of 0.87 nM. CHIR 98014 causes GS stimulation in CHO-IR cells and rat hepatocytes, with EC50s of 106 nM and 107 nM, respectively[1]. CHIR-98014 (1 μM) reduces the viability of ES-CCE cells by 52%, with IC50 of 1.1 μM. Moreover, CHIR-98014 in combination with CHIR-99021 results in a significant activation of the Wnt/beta-catenin pathway in ES-D3 cells. In CHIR-98014 treated cells, the T gene expression is induced up to 2,500-fold. CHIR-98014 (1 μM) also yields around 50% Brachyury-positive cells, with EC50 of 0.32 μM[2]. CHIR98014 (10 μM) prevents loss of neurites caused by 20 μM PrP1-30 in cortical and hippocampal neurons, and substantially decreases the amount of dead cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 252935-94-7
-
Appearance Solid
-
Molecular Weight 486.31
-
Formula C20H17Cl2N9O2
-
Color Light yellow to yellow
-
SMILES
ClC1=CC(Cl)=CC=C1C2=NC(NCCNC3=CC=C([N+]([O-])=O)C(N)=N3)=NC=C2N4C=CN=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
Derivation of totipotent-like stem cells with blastocyst-like structure forming potential. [Abstract]2022 Jun;32(6):513-529. PMID: 35508506 -
Cancer Res
A GYS2/p53 Negative Feedback Loop Restricts Tumor Growth in HBV-Related Hepatocellular Carcinoma. [Abstract]2019 Feb 1;79(3):534-545. PMID: 30584071 -
Adv Sci (Weinh)
PDZK1-ULK1 Axis Triggers Lipophagy to Inhibit Tumor Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. [Abstract]2026 Apr;13(23):e11606. PMID: 41698049 -
Sci Adv
Caspase-3/7 deficiency results in enhanced intestinal inflammation and reduced tumorigenesis. [Abstract]2026 Mar 20;12(12):eadz5906. PMID: 41861024 -
Food Chem Toxicol
Mechanistic insights into AKT1/GSK3β/CD36 axis regulation in ZLY06-induced hepatic lipid metabolism dysfunction and protective intervention via AKT activation strategies. [Abstract]2025 Oct:204:115628. PMID: 40633829 -
Hum Cell
β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression. [Abstract]2024 Jul;37(4):1156-1169. PMID: 38814517 -
SLAS Discov
Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ. [Abstract]2024 Nov 5;29(8):100191. PMID: 39510350 -
-
-
Solvent & Solubility
DMSO : 12.5 mg/mL (25.70 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing kinase, peptide substrate, and any activators. Information on the kinase concentration, peptide substrate, and activator for these assays is as follows: GSK-3α (27 nM, and 0.5 μM biotin-CREB peptide); GSK-3β (29 nM, and 0.5 μM biotin-CREB peptide); cdc2 (0.8 nM, and 0.5 μM biotin histone H1 peptide); erk2 (400 units/mL, and myelin basic protein-coated Flash Plate); PKC-α (1.6 nM, 0.5 μM biotin-histone H1 peptide, and 0.1 mg/mL phosphatidylserine + 0.01 mg/mL diglycerides); PKC-ζ (0.1 nM, 0.5 μM biotin-PKC-86 peptide, and 50 μg/mL phosphatidylserine + 5 μg/mL diacylglycerol); akt1 (5.55 nM, and 0.5 μM biotin phospho-AKT peptide); p70 S6 kinase (1.5 nM, and 0.5 μM biotin-GGGKRRRLASLRA); p90 RSK2 (0.049 units/mL, and 0.5 μM biotin-GGGKRRRLASLRA); c-src (4.1 units/mL, and 0.5 μM biotin-KVEKIGEGTYGVVYK); Tie2 (1 μg/mL, and 200 nM biotin-GGGGAPEDLYKDFLT); flt1 (1.8 nM, and 0.25 μM KDRY1175 [B91616] biotin-GGGGQDGKDYIVLPI-NH2); KDR (0.95 nM, and 0.25 μM KDRY1175 [B91616] biotin-GGGGQDGKDYIVLPI-NH2); bFGF receptor tyrosine kinase (RTK; 2 nM, and 0.25 μM KDRY1175 [B91616] biotin-GGGGQDGKDYIVLPI-NH2); IGF1 RTK (1.91 nM, and 1 μM biotin-GGGGKKKSPGEYVNIEFG-amide); insulin RTK (using DG44 IR cells); AMP kinase (470 units/mL, 50 μM SAMS peptide, and 300 μM AMP); pdk1 (0.25 nM, 2.9 nM unactivated Akt, and 20 μM each of DOPC and DOPS + 2 μM PIP3); CHK1 (1.4 nM, and 0.5 μM biotin-cdc25 peptide); CK1-ε (3 nM, and 0.2 μM biotin-peptide); DNA PK (see 31); and phosphatidylinositol (PI) 3-kinase (5 nM, and 2 μg/mL PI). Test compounds or controls are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 h, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 min, and counted in a scintillation counter. All steps are performed at room temperature. Inhibition is calculated as 100% × (inhibited − no enzyme control)/(DMSO control − no enzyme control)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The viability of the mouse ES cells is determined after exposure to different concentrations of GSK3 inhibitors for three days using the MTT assay. The decrease of MTT activity is a reliable metabolism-based test for quantifying cell viability; this decrease correlates with the loss of cell viability. 2,000 cells are seeded overnight on gelatine-coated 96-well plates in LIF-containing ES cell medium. On the next day the medium is changed to medium devoid of LIF and with reduced serum and supplemented with 0.1-1 μM BIO, or 1-10 μM SB-216763, CHIR-99021 or CHIR-98014. Basal medium without GSK3 inhibitors or DMSO is used as control. All tested conditions are analyzed in triplicates[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Blood is obtained by shallow tail snipping at lidocaine-anesthetized tips. Blood glucose is measured directly or heparinized plasma is collected for measurement of glucose or insulin. Animals are prebled and randomized to vehicle control or GSK-3 inhibitor treatment groups. For glucose tolerance tests (GTTs), animals are fasted throughout the procedure with food removal early in the morning, 3 h before first prebleed (db/db mice), or the previous night, 16 h before the bleed (ZDF rats). When the time course of plasma glucose and insulin changes in fasting ZDF rats is measured, food is removed ∼16 h before test agent administration. The glucose challenges in the GTT are 1.35 g/kg i.p. (ipGTT) or 2 g/kg via oral gavage (oGTT). Test inhibitors are formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. [Content Brief]
[2]. Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res Notes. 2014 Apr 29;7:273. [Content Brief]
[3]. Zajkowski T, et al. Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2228-39. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0563 mL | 10.2815 mL | 20.5630 mL | 51.4075 mL |
| 5 mM | 0.4113 mL | 2.0563 mL | 4.1126 mL | 10.2815 mL | |
| 10 mM | 0.2056 mL | 1.0282 mL | 2.0563 mL | 5.1408 mL | |
| 15 mM | 0.1371 mL | 0.6854 mL | 1.3709 mL | 3.4272 mL | |
| 20 mM | 0.1028 mL | 0.5141 mL | 1.0282 mL | 2.5704 mL | |
| 25 mM | 0.0823 mL | 0.4113 mL | 0.8225 mL | 2.0563 mL |